Alclofenac

Alclofenac

SCHEMBL25703

C=CCOc1ccc(CC(=O)O)cc1Cl

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1

The experimentally established mechanism targets of Alclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 2/20 0.62
GAA P10253 3/20 0.54
TSHR P16473 3/20 0.54
CA2 P00918 1/20 0.51
TDP1 Q9NUW8 3/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 3/20 0.45
ALDH1A1 P00352 2/20 0.44
NFKB1 P19838 1/20 0.44
LTB4R Q15722 2/20 0.44
LTB4R2 Q9NPC1 2/20 0.44
KDM1A O60341 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
PTGDR Q13258 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alclofenac SCHEMBL29350515 1.00 PPARD (0.62) PPARDGAATSHRCA2TDP1
Alclofenac SCHEMBL10600369 1.00 PPARD (0.62) PPARDGAATSHRCA2TDP1
Alclofenac SCHEMBL6246536 0.99 PPARD (0.60) PPARDGAATSHRCA2TDP1
SCHEMBL11462158 0.95 PPARD (0.57) PPARDGAATSHRCA2NPC1
Alclofenac SCHEMBL28898335 0.95 PPARD (0.57) PPARDGAATSHRCA2TDP1
Alclofenac SCHEMBL3500031 0.92 PPARD (0.55) PPARDGAATSHRCA2TDP1
Alclofenac SCHEMBL3714811 0.89 PPARD (0.52) PPARDGAATSHRCA2TDP1
SCHEMBL11460461 0.88 PPARD (0.52) PPARDGAATSHRCA2NPC1
SCHEMBL11013101 0.88 GAA (0.50) PPARDGAATSHRTDP1NPC1
SCHEMBL11480256 0.88 PPARD (0.51) PPARDGAATSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 14904 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000741-A1 METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE ACERAGEN INC (US) 2026-01-01 US claimed
EP-4628080-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRUG-RELATED PEPTIC ULCER COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Jeil Pharmaceutical Co., Ltd. (KR) 2025-10-08 EP claimed
EP-4525870-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT Corcept Therapeutics Incorporated (US) 2025-03-26 EP claimed
US-20250041208-A1 NEW INJECTABLE COMBINATION FORMULATION NANEXA AB (SE) 2025-02-06 US claimed
CN-119317433-A Methods for treating cushing's syndrome and liver disease and reducing hepatotoxicity of other drugs taken by patients 科赛普特治疗学股份有限公司 2025-01-14 CN claimed
US-12161726-B2 Biomimetic vesicles and uses thereof OHIO STATE INNOVATION FOUNDATION (US) 2024-12-10 US claimed
EP-3508501-B1 USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS H LUNDBECK AS (DK) 2024-11-06 EP claimed
EP-4444277-A1 NEW INJECTABLE COMBINATION FORMULATION Nanexa AB (SE) 2024-10-16 EP claimed
CN-118647367-A Novel injectable combination formulations 南爱克萨股份公司 2024-09-13 CN claimed
US-20240299348-A1 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE CARAWAY THERAPEUTICS, INC. 2024-09-12 US claimed
EP-0016460-B1 SALICYLAMIDE ESTERS HAVING THERAPEUTICAL ACTIVITY, PROCESS FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITION NEOPHARMED S.p.A. (IT) 1982-07-28 EP claimed
EP-0055870-A1 Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same MERCK & CO. INC. (US) 1982-07-14 EP claimed
EP-0051278-A1 Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1982-05-12 EP claimed
EP-0050385-A1 Piridoxine derivatives, a process for their preparation and related pharmaceutical compositions D and D S.r.l. (IT) 1982-04-28 EP claimed
US-4309421-A Stabilized parenterally administrable solutions A. NATTERMANN & CIE. GMBH (DE) 1982-01-05 US claimed
EP-0040899-A2 Method of delivering drug with aid of effervescent activity generated in environment of use ALZA CORPORATION (US) 1981-12-02 EP claimed
US-4279926-A PHENYL ALKANOIC ACID SALT OF AN AMINO ACID SPA-SOCIETA PRODOTTI ANTIBIOTICI S.P.A. (IT) 1981-07-21 US claimed
US-4268685-A Salicylamide esters and related pharmaceutical composition NEOPHARMED S.P.A. (IT) 1981-05-19 US claimed
US-4233304-A ANTIINFLAMMATORY AGENTS CRINOS INDUSTRIA FARMACOBIOLOGICA S.P.A. (IT) 1980-11-11 US claimed
EP-0016460-A1 Salicylamide esters having therapeutical activity, process for their preparation and related pharmaceutical composition NEOPHARMED S.p.A. (IT) 1980-10-01 EP claimed